Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 10/20 | 0.36 |
| ▸ | CES1 | P23141 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038964 | 0.81 | CES2 (0.39) | CES2CES1ALDH1A1USP2SLCO1B1 | |
| SCHEMBL5035200 | 0.79 | CES2 (0.38) | CES2CES1ALDH1A1EGFRSMN1; SMN2 | |
| SCHEMBL28395946 | 0.79 | CES2 (0.38) | CES2CES1ALDH1A1EGFRSMN1; SMN2 | |
| SCHEMBL10775308 | 0.79 | CES2 (0.37) | CES2CES1ALDH1A1USP2SMN1; SMN2 | |
| Benzil SCHEMBL28453926 | 0.76 | CES2 (0.58) | CES2CES1ALDH1A1USP2SLCO1B1 | |
| Benzil SCHEMBL2341683 | 0.76 | CES2 (0.58) | CES2CES1ALDH1A1USP2SLCO1B1 | |
| SCHEMBL16210771 | 0.76 | CES1 (0.39) | CES2CES1ALDH1A1USP2SLCO1B1 | |
| SCHEMBL28821597 | 0.76 | CES1 (0.39) | CES2CES1ALDH1A1USP2SLCO1B1 | |
| SCHEMBL28929921 | 0.75 | ALDH1A1 (0.39) | CES2CES1ALDH1A1HIF1APRKCA | |
| SCHEMBL6776415 | 0.72 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4455292-A | Radiological contrast composition and methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1984-06-19 | — | — | US | claimed |
| US-20060142207-A1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-7001888-B2 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040029815-A1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003082301-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4455292-A | Radiological contrast composition and methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029815-A1 | Compositions and methods for treating cancer | SLC2A2, SLC2A1, SLC2A3 | CES2 421/4885CES1 742/4885ALDH1A1 987/4885 |
| US-20060142207-A1 | Compositions and methods for treating cancer | SLC2A2, SLC2A1, SLC2A3 | CES2 421/4885CES1 742/4885ALDH1A1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.